公开(公告)号：EP1846363A2

公开(公告)日：2007-10-24

申请号：EP06717418.5

申请日：2006-01-05

Applicant: ABBOTT LABORATORIES

Inventor： PATEL, Jyoti, R. ,  SHUAI, Qi ,  LINK, James, T. ,  ROHDE, Jeffrey, J. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  WINN, Martin ,  YONG, Hong ,  YEH, Vince, S.

IPC: C07C235/14 ,  C07C317/16 ,  C07C323/41 ,  C07D257/04 ,  C07D233/54 ,  C07D261/08 ,  C07D213/64 ,  C07D207/48 ,  A61K31/4402 ,  A61P3/10

CPC classification number: C07C233/23 ,  C07C235/14 ,  C07C237/24 ,  C07C255/31 ,  C07C255/47 ,  C07C259/16 ,  C07C311/08 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07C317/22 ,  C07C317/30 ,  C07C317/44 ,  C07C323/41 ,  C07C323/60 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D207/48 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：EP1501846B1

公开(公告)日：2009-03-18

申请号：EP03731049.7

申请日：2003-04-25

Applicant: ABBOTT LABORATORIES

Inventor： GU, Yugui ,  MA, Zhenkun ,  YONG, Hong

IPC: C07H17/08 ,  A61K31/7048 ,  A61P31/04

CPC classification number: C07H17/08

Abstract: Antibacterial compounds having formula (I) and formula (II), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods for prophylaxis or treatment of bacterial infections using the compounds are disclosed.

公开(公告)号：EP1846362A2

公开(公告)日：2007-10-24

申请号：EP06717579.4

申请日：2006-01-05

Applicant: ABBOTT LABORATORIES

Inventor： ROHDE, Jeffrey, J. ,  SHUAI, Qi ,  LINK, James, T. ,  PATEL, Jyoti, R. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  YONG, Hong ,  KURUKULASURIYA, Ravi ,  YEH, Vince

IPC: C07C233/63 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24 ,  A61K31/165 ,  A61K31/4409 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07D207/277 ,  C07C233/11 ,  C07C233/52 ,  C07C233/58 ,  C07C233/63 ,  C07C237/24 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D211/78 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：EP1560811B9

公开(公告)日：2008-03-05

申请号：EP03774478.6

申请日：2003-09-15

Applicant: ABBOTT LABORATORIES

Inventor： MADAR, David ,  PEI, Zhonghua ,  PIREH, Daisy ,  DJURIC, Stevan, W. ,  WIEDEMAN, Paul, E. ,  YONG, Hong ,  MICHMERHUIZEN, Melissa, J. ,  KOPECKA, Hana ,  LI, Xiaofeng ,  LONGENECKER, Kenton ,  SHAM, Hing, L. ,  STEWART, Kent, D. ,  SZCZEPANKIEWICZ, Bruce, G.

IPC: C07D207/00

CPC classification number: C07D207/27 ,  C07D207/16 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R1,R2 and R3 have the definitions given in the description.

公开(公告)号：EP1579864A1

公开(公告)日：2005-09-28

申请号：EP05104506.0

申请日：2003-04-23

Applicant: ABBOTT LABORATORIES

Inventor： MA, Zhenkun ,  DJURIC, Stevan ,  FLORJANCIC, Alan S. ,  YONG, Hong ,  GU, Yugui

IPC: A61K31/7048 ,  C07H17/08

CPC classification number: C07H17/08

Abstract: Antibacterial compounds having formula (II), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates employed in the processes, compositions containing the compounds, and methods for prophylaxis or treatment of bacterial infections in a fish or a mammal using the compounds are disclosed.

公开(公告)号：EP1560811B1

公开(公告)日：2007-08-01

申请号：EP03774478.6

申请日：2003-09-15

Applicant: ABBOTT LABORATORIES

Inventor： MADAR, David ,  PEI, Zhonghua ,  PIREH, Daisy ,  DJURIC, Stevan, W. ,  WIEDEMAN, Paul, E. ,  YONG, Hong ,  MICHMERHUIZEN, Melissa, J. ,  KOPECKA, Hana ,  LI, Xiaofeng ,  LONGENECKER, Kenton ,  SHAM, Hing, L. ,  STEWART, Kent, D. ,  SZCZEPANKIEWICZ, Bruce, G.

IPC: C07D207/00

CPC classification number: C07D207/27 ,  C07D207/16 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R1,R2 and R3 have the definitions given in the description.

公开(公告)号：EP1560811A2

公开(公告)日：2005-08-10

申请号：EP03774478.6

申请日：2003-09-15

Applicant: Abbott Laboratories

Inventor： MADAR, David ,  PEI, Zhonghua ,  PIREH, Daisy ,  DJURIC, Stevan, W. ,  WIEDEMAN, Paul, E. ,  YONG, Hong ,  FEENSTRA, Melissa, J. ,  KOPECKA, Hana ,  LI, Xiaofeng ,  LONGENECKER, Kenton ,  SHAM, Hing, L. ,  STEWART, Kent, D. ,  SZCZEPANKIEWICZ, Bruce, G.

IPC: C07D207/00

CPC classification number: C07D207/27 ,  C07D207/16 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R1,R2 and R3 have the definitions given in the description.

公开(公告)号：EP1499326A1

公开(公告)日：2005-01-26

申请号：EP03719889.2

申请日：2003-04-23

Applicant: Abbott Laboratories

Inventor： MA, Zhenkun ,  DJURIC, Stevan ,  FLORJANCIC, Alan, S. ,  YONG, Hong ,  GU, YUGUI

IPC: A61K31/7048 ,  C07H17/08

CPC classification number: C07H17/08

Abstract: Antibacterial compounds having formula (I) and formula (II), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates employed in the processes, compositions containing the compounds, and methods for prophylaxis or treatment of bacterial infections in a fish or a mammal using the compounds are disclosed.

公开(公告)号：EP1846363B1

公开(公告)日：2012-04-25

申请号：EP06717418.5

申请日：2006-01-05

Applicant: Abbott Laboratories

Inventor： PATEL, Jyoti, R. ,  SHUAI, Qi ,  LINK, James, T. ,  ROHDE, Jeffrey, J. ,  DINGES, Jurgen ,  SORENSEN, Bryan, K. ,  WINN, Martin ,  YONG, Hong ,  YEH, Vince, S.

IPC: C07C235/14 ,  C07C317/16 ,  C07C323/41 ,  C07D257/04 ,  C07D233/54 ,  C07D261/08 ,  C07D213/64 ,  C07D207/48 ,  A61K31/4402 ,  A61P3/10

CPC classification number: C07C233/23 ,  C07C235/14 ,  C07C237/24 ,  C07C255/31 ,  C07C255/47 ,  C07C259/16 ,  C07C311/08 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07C317/22 ,  C07C317/30 ,  C07C317/44 ,  C07C323/41 ,  C07C323/60 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D207/48 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：EP1919854A2

公开(公告)日：2008-05-14

申请号：EP06790057.1

申请日：2006-08-25

Applicant: ABBOTT LABORATORIES

Inventor： PEI, Zhonghua ,  VON GELDERN, Thomas ,  MADAR, David, J. ,  LI, Xiaofeng ,  BASHA, Fatima ,  YONG, Hong ,  LONGENECKER, Kenton, L. ,  BACKES, Bradley, J. ,  JUDD, Andrew, S. ,  MULHERN, Mathew, M. ,  STEWART, Kent, D.

IPC: C07C211/40 ,  C07C211/54 ,  C07C211/62 ,  C07D213/38 ,  C07D213/68 ,  C07D317/64 ,  C07D487/04 ,  A61K31/137

CPC classification number: C07C211/48 ,  C07C211/40 ,  C07C217/52 ,  C07C217/54 ,  C07C217/74 ,  C07C217/84 ,  C07C217/86 ,  C07C225/22 ,  C07C229/42 ,  C07C229/48 ,  C07C229/60 ,  C07C233/43 ,  C07C233/78 ,  C07C235/46 ,  C07C237/24 ,  C07C237/30 ,  C07C237/42 ,  C07C255/54 ,  C07C255/58 ,  C07C311/22 ,  C07C311/36 ,  C07C317/22 ,  C07C317/36 ,  C07C2601/14 ,  C07C2601/16 ,  C07D207/16 ,  C07D209/08 ,  C07D209/48 ,  C07D211/46 ,  C07D211/60 ,  C07D211/62 ,  C07D213/30 ,  C07D213/38 ,  C07D213/64 ,  C07D213/68 ,  C07D213/74 ,  C07D213/82 ,  C07D217/04 ,  C07D263/56 ,  C07D263/60 ,  C07D277/04 ,  C07D277/64 ,  C07D295/135 ,  C07D295/185 ,  C07D295/205 ,  C07D317/66 ,  C07D319/18 ,  C07D333/34 ,  C07D333/38 ,  C07D409/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, metabolic syndrome , hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.

Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，代谢综合征，高胰岛素血症，肥胖症，动脉粥样硬化，各种免疫调节疾病， 和其他疾病。